Oxford Ledge
Search
No licensed closing price on file for XAIR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.
Beyond Air, Inc. (NASDAQ: XAIR) is a medical device company. Figures from SEC EDGAR; updated 2026-10-21 02:35 UTC.
Beyond Air is a medical device and biopharmaceutical company that develops nitric oxide generators and delivery systems, primarily the LungFit platform, which produces nitric oxide from ambient air. The company's first product, LungFit PH, received FDA approval in June 2022 for treating a lung condition in newborns called persistent pulmonary hypertension, and began U.S. marketing in September 2022; it also received European CE mark approval in November 2024 for additional uses in infants and children undergoing heart surgery and for certain severe lung infections.
Summarized from Beyond Air, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗
| Valuation | |
| Return on equity | -542.75% |
Beyond Air is a medical device and biopharmaceutical company that develops nitric oxide generators and delivery systems, primarily the LungFit platform, which produces nitric oxide from ambient air.
Beyond Air, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-09. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 02:35 UTC. This page is also available as JSON at /api/data?ticker=XAIR and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for XAIR and 5,000+ tickers.
Create a free account — keep XAIRGET /api/data?ticker=XAIR
This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt